Trial · NCT02285153
Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit
NCT02285153, Phase 3, Terminated, Medical University of Vienna; results first posted 2019-12-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit. Trials, record NCT02285153. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02285153
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit
- NCT number
- NCT02285153
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 15 participants, actual
- Lead sponsor
- Medical University of Vienna
- Conditions
- Critical Illness
- Interventions
- Acetylsalicylic acid lysinate, 0.9% sodium-chloride solution
- First posted
- 2014-11-06
- Last updated
- 2019-12-18
- Other registries' IDs
- eudract:2012-002235-29
- Results first posted
- 2019-12-18
- Limitations and caveats
The study had to be terminated because of a poor recruitment rate. Thus, all results need to be interpreted with great caution. Patients were critically ill. Hence, the occurrence of adverse events should be interpreted accordingly.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 28-day Mortality | 28-days | Standard outcome measure of investigational intensive care unit trials. |
| Secondary | Intensive Care Unit Mortality | up to 90 days after inclusion | Mortality of patients during their intensive care unit stay, 90 day mortality, potentially longer |
| Secondary | Number of Patients Who Developed a Thrombotic or Embolic Complications During the Trial | average 28 days | clinically relevant thromboembolic events assessed by standard care, potentially longer |
| Secondary | Bleeding Incidences | average 28days | all bleeding incidence during the intensive care unit stay will be recorded. major bleeding criteria are taken from the Thrombolysis in myocardial infarction study (TIMI-Triton-38), potentially longer |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 28-day Mortality | 28-days | modified Intention to treat population (all patients who received at least a single dose of acetylsalicylic acid) | participants | NUMBER |
| SECONDARY | Intensive Care Unit Mortality | up to 90 days after inclusion | participants | NUMBER | |
| SECONDARY | Number of Patients Who Developed a Thrombotic or Embolic Complications During the Trial | average 28 days | participants | NUMBER | |
| SECONDARY | Bleeding Incidences | average 28days | counts | NUMBER |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 28-day Mortality | Acetylsalicylic Acid Lysinate | 1 | participants | ||
| 28-day Mortality | 0.9% Sodium-chloride Solution | 1 | participants | ||
| Intensive Care Unit Mortality | Acetylsalicylic Acid Lysinate | 2 | participants | ||
| Intensive Care Unit Mortality | 0.9% Sodium-chloride Solution | 1 | participants | ||
| Number of Patients Who Developed a Thrombotic or Embolic Complications During the Trial | Acetylsalicylic Acid Lysinate | 0 | participants | ||
| Number of Patients Who Developed a Thrombotic or Embolic Complications During the Trial | 0.9% Sodium-chloride Solution | 1 | participants | ||
| Bleeding Incidences | Acetylsalicylic Acid Lysinate | 1 | counts | ||
| Bleeding Incidences | 0.9% Sodium-chloride Solution | 0 | counts |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Acetylsalicylic Acid Lysinate | 7 | |
| Overall Study | STARTED | 0.9% Sodium-chloride Solution | 8 | |
| Overall Study | COMPLETED | Acetylsalicylic Acid Lysinate | 6 | |
| Overall Study | COMPLETED | 0.9% Sodium-chloride Solution | 8 | |
| Overall Study | NOT COMPLETED | Acetylsalicylic Acid Lysinate | 1 | |
| Overall Study | NOT COMPLETED | 0.9% Sodium-chloride Solution | 0 |
Source ClinicalTrials.gov
Adverse events36
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Bleeding | Vascular disorders | Acetylsalicylic Acid Lysinate | 1 | 7 | 1 |
| other | Bleeding | Vascular disorders | 0.9% Sodium-chloride Solution | 0 | 8 | 0 |
| other | atrial fibrillation | Cardiac disorders | Acetylsalicylic Acid Lysinate | 0 | 7 | 0 |
| other | atrial fibrillation | Cardiac disorders | 0.9% Sodium-chloride Solution | 1 | 8 | 1 |
| other | Pneumothorax | Respiratory, thoracic and mediastinal disorders | Acetylsalicylic Acid Lysinate | 0 | 7 | 0 |
| other | Pneumothorax | Respiratory, thoracic and mediastinal disorders | 0.9% Sodium-chloride Solution | 1 | 8 | 1 |
| other | Pleural effusion | Respiratory, thoracic and mediastinal disorders | Acetylsalicylic Acid Lysinate | 1 | 7 | 1 |
| other | Pleural effusion | Respiratory, thoracic and mediastinal disorders | 0.9% Sodium-chloride Solution | 0 | 8 | 0 |
| other | Delirium | Nervous system disorders | Acetylsalicylic Acid Lysinate | 2 | 7 | 2 |
| other | Delirium | Nervous system disorders | 0.9% Sodium-chloride Solution | 1 | 8 | 1 |
1 to 10 of 36Source ClinicalTrials.gov
See all 36 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Acetylsalicylic Acid Lysinate | 2 | 7 |
| Total, all-cause mortality | 0.9% Sodium-chloride Solution | 1 | 8 |
| Total, other adverse events | Acetylsalicylic Acid Lysinate | 4 | 7 |
| Total, other adverse events | 0.9% Sodium-chloride Solution | 6 | 8 |
| Total, serious adverse events | Acetylsalicylic Acid Lysinate | 2 | 7 |
| Total, serious adverse events | 0.9% Sodium-chloride Solution | 3 | 8 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 19770746 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons5
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Acetylsalicylic Acid Lysinate vs 0.9% Sodium-chloride Solution: Number of Patients Who Developed a Thrombotic or Embolic Complications During the Trial | Trial comparisons |
| Acetylsalicylic Acid Lysinate vs 0.9% Sodium-chloride Solution: Intensive Care Unit Mortality | Trial comparisons |
| Acetylsalicylic Acid Lysinate vs 0.9% Sodium-chloride Solution: deaths from any cause | Trial comparisons |
| Acetylsalicylic Acid Lysinate vs 0.9% Sodium-chloride Solution: 28-day Mortality | Trial comparisons |
| Acetylsalicylic Acid Lysinate vs 0.9% Sodium-chloride Solution: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02285153
GET https://conductscience.org/api/trials/v1/NCT02285153/events?page=2